EF Hutton Initiates Coverage On UroGen Pharma with Buy Rating, Announces Price Target of $25

Benzinga · 10/14 12:11
EF Hutton analyst Jason Kolbert initiates coverage on UroGen Pharma (NASDAQ:URGN) with a Buy rating and announces Price Target of $25.